Due to the Christmas holiday, recognized on Friday, Dec. 25, and the New Year's holiday, recognized on Friday, Jan. 1, Mayo Medical Laboratories’ specimen pickup and delivery schedule will be altered. To ensure that your specimen vitality and turn-around time are not affected, plan ahead and note that no pickups or deliveries will be made on Dec. 25 or Jan. 1 by our couriers or FedEx.
Mayo Clinic has taken the top spot on the Gartner Inc. annual Healthcare Supply Chain Top 25 ranking. The 2015 ranking recognizes companies across the health-care value chain that demonstrate leadership in improving patient care and lowering costs.
Mayo Medical Laboratories’ Molecular Genetics Laboratory Receives National Institutes of Health Grant
Stephen Thibodeau Ph.D., a consultant in Mayo Medical Laboratories’ Molecular Genetics Laboratory, along with Iftikhar Kullo, M.D., has received a four-year grant from the National Institutes of Health (NIH), which will support research that incorporates DNA sequence information into electronic medical records.
Viewics and Mayo Clinic Team Up to Use Data Analytics to Better Serve Patients and Laboratory Clients
Viewics, Inc., a provider of health care analytics solutions, and Mayo Clinic recently signed an agreement that will use Viewics analytics platform to drive key initiatives for safety, service, costs, and quality.
Mayo Medical Laboratories (MML) has launched new website updates, which include navigation enhancements to improve user experience and a significant redesign of our 'About Us' section.
Due to the Labor Day holiday, observed Monday, Sept. 7 in the United States, Mayo Medical Laboratories' specimen pickup and delivery schedule will be altered. To ensure that your specimen vitality and turn-around time are not affected, plan ahead and note that no pickups or deliveries will be made on Sept. 7 by our couriers or FedEx.
National Cancer Institute Awards SPORE Grant to Multiple Myeloma Research Team From Mayo Clinic Cancer Center
A team of Mayo Clinic Cancer Center scientists has been awarded a Specialized Program of Research Excellence (SPORE) grant in multiple myeloma from the National Cancer Institute. The Mayo Clinic Cancer Center is one of only three cancer centers to receive a SPORE grant for multiple myeloma cancer research.
On Tuesday, Aug. 18, DLMP staff and local Rochester leadership celebrated the grand opening of the Superior Drive Support Center expansion building. More than 1,000 employees and guests toured the new addition during the open house.
Diadexus and Mayo Clinic Join Forces on PLAC Activity Test to Improve Patient Care for Cardiovascular Diseases
Diadexus, Inc., a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, and Mayo Clinic recently signed an agreement to collaborate in the areas of education, research, and innovation on the PLAC® Test for Lp‑PLA2 Activity. The test, which has been cleared by the FDA, is used to help identify risk for coronary heart disease in patients with no history of cardiovascular events.
Mayo Clinic reports that in the summer months, its physicians see an increase in patients being treated, and even hospitalized, for tick-borne illnesses. To protect you against tick-borne diseases, the Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory Mayo Medical Laboratories have developed “The ABCs of Ticks” flash cards.
University of Missouri Health Care—Mayo Medical Laboratories Collaboration Will Benefit Patients, Providers
University of Missouri Health Care has selected Mayo Medical Laboratories as its primary reference laboratory for advanced laboratory testing. The collaboration will make test results available to providers and patients faster through MU Health Care’s electronic medical record. It is also expected to save MU Health Care more than $1 million annually.
For the fourth year in a row, Mayo Laboratory Inquiry has been named a Center of Excellence by BenchmarkPortal, a global leader in the contact center industry.
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. A team of researchers led by Mayo Clinic has found a promising way to circumvent this obstacle.